Self-Selected Versus Physiotherapist-Prescribed Resistance Training Program In People With Chronic Low Back Pain
MyBackExercise
Efficacy of a Self-Selected Resistance Training Program Compared With a Physiotherapist-Prescribed Resistance Training Program in People With Chronic Low Back Pain (MyBack Exercise): A Randomized Control Pilot Study
1 other identifier
interventional
34
0 countries
N/A
Brief Summary
Chronic low back pain is a public health issue affecting over 20% of the Spanish population, causing disability, reduced quality of life, and work absenteeism. Over the past decades, the benefits of physical exercise for improving symptoms in patients with chronic low back pain have been studied. Exercise has also been shown to improve quality of life, general health, self-efficacy, and fear of pain, regardless of pathology. Research on the effect of physical exercise in chronic low back pain patients has shown promising results. Therefore, the therapeutic exercise program proposed in this study may help participants adopt healthy habits that positively impact their quality of life. This will be a clinical trial in patients with chronic low back pain. The main purpose of the study is to evaluate the efficacy of a self-selected resistance training program versus physiotherapist-prescribed exercises in improving pain intensity and disability in adults with chronic low back pain. Secondary objectives include evaluating differences between the two groups after 12 weeks in treatment satisfaction, degree of compliance, kinesiophobia, self-efficacy, muscle endurance, and lumbar electromyographic activity. If you agree to participate, a member of the research team experienced in exercise programs for chronic low back pain will instruct you on how to perform the program. The follow-up study will include 34 participants randomly assigned to two groups: one group performing self-selected resistance exercises, and one group performing physiotherapist-prescribed exercises. The study will last 12 weeks, assessing your condition at the start and end of the study. You will complete questionnaires on pain intensity (Numerical Pain Rating Scale, NPRS), disability (Oswestry Disability Index, ODI), treatment satisfaction (CRES-4), adherence to treatment, kinesiophobia (TSK-11), self-efficacy (Pain Self-Efficacy Questionnaire, PSEQ), muscle endurance (Biering-Sørensen test), and surface electromyographic activity of the erector spinae (longissimus) muscle (sEMG-ESL) using the mDurance® device. POTENTIAL BENEFITS AND RISKS OF PARTICIPATION Expected direct benefits of participation may include improvements in pain intensity, disability, treatment satisfaction, adherence to therapeutic exercise, kinesiophobia, self-efficacy, muscle endurance, and electromyographic activity. However, it is possible that you may not experience any personal benefit. The information obtained will contribute to scientific knowledge about CLBP and may help others in the future. ALTERNATIVE TREATMENTS Chronic low back pain is a pathological entity with extensive study, which can present different conservative therapeutic options, such as psychological therapy, regular physical exercise and the adoption of healthy habits. COMPENSATION Participation in this study will not incur any costs for you. OTHER RELEVANT INFORMATION Any new information discovered during your participation that may affect your willingness to participate in the study will be communicated to you by your doctor as soon as possible. If you decide to withdraw your consent to participate in this study, no new data will be added to the database, and if samples have already been collected, you may request the destruction of all previously obtained, identifiable samples to avoid further analysis. You should also be aware that you may be excluded from the study if the sponsor or researchers deem it necessary, either for safety reasons or because they believe you are not complying with the established procedures. In either case, you will receive a clear explanation of the reason for your withdrawal from the study. The sponsor may suspend the study for any of the reasons stipulated in current legislation. By signing the attached consent form, you agree to comply with the study procedures explained to you. When your participation is over, you will receive the best available treatment that your doctor considers most appropriate for your condition.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Sep 2026
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 29, 2026
CompletedFirst Posted
Study publicly available on registry
August 4, 2026
CompletedStudy Start
First participant enrolled
September 1, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2027
Study Completion
Last participant's last visit for all outcomes
December 1, 2027
August 4, 2026
May 1, 2026
6 months
July 29, 2026
July 29, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Pain-related distribution and intensity
Pain distribution will be evaluated using a 45-region body map to identify painful body areas. Pain intensity will be measured separately for low back pain and leg pain using the Numerical Pain Rating Scale (NPRS), a continuous measure ranging from 0 (no pain) to 10 (worst imaginable pain), with higher scores indicating greater pain intensity.
From enrollment to the end of treatment at 12 weeks
Disability
Disability will be measured as a discrete quantitative variable using the Oswestry Disability Index (ODI), with a total score ranging from 0 to 50 points, reflecting the degree of functional limitation associated with CLBP.
From enrollment to the end of treatment at 12 weeks
Secondary Outcomes (6)
Treatment satisfaction
From T1 (4 weeks) to the end of treatment at 12 weeks
Degree of compliance
From T1 (4 weeks) to the end of treatment at 12 weeks
Kinesiophobia
From enrollment to the end of treatment at 12 weeks
Self-efficacy
From enrollment to the end of treatment at 12 weeks
Muscle endurance
From enrollment to the end of treatment at 12 weeks
- +1 more secondary outcomes
Study Arms (2)
Arm experimental
EXPERIMENTALArm control
ACTIVE COMPARATORInterventions
The control group will carry out a physiotherapist-prescribed RT programme. Participants in this group will not be able to choose their exercises and will perform six exercises: push-ups, row, squat, deadlift, abdominal crunch and back extension.
The experimental group will follow a programme with different RT options. This proposal will be displayed on a board with detailed images of the exercises in the treatment centre. Each patient will individually choose six exercises daily; two for each body part (upper limb; lower limb; trunk). Each patient's individual choice of exercises will be recorded using checklists. Under no circumstances will the physiotherapist guidance take precedence; the clinician will refrain from expressing their preferences and beliefs regarding the selected-exercise. The patient will have the option to repeat or vary the exercises throughout the training programme, if they so decide. For both groups, the treatment materials will include variable-resistance elastic bands, adjustable dumbbells, chairs, and a roman chair. Therapeutic supervision will be provided face-to-face for all study participants by three experimented physiotherapists from the research group.
Eligibility Criteria
You may not qualify if:
- Lumbar radiculopathy or radicular pain syndrome, defined by clinical signs of nerve root involvement (e.g., dermatomal pain, neurological deficits, or positive neurodynamic tests)
- Serious spinal or non-spinal pathology explaining low back pain, identified through clinical assessment (e.g., malignancy, vertebral fracture, spinal infection, cauda equina syndrome, inflammatory spinal disease, vascular, visceral or other serious causes).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Cadizlead
- Instituto de Investigacion Sanitaria La Fecollaborator
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
José A. Moral Muñoz, PT, PhD
University of Cadiz (Spain)
- STUDY DIRECTOR
Álvaro José Rodríguez Domínguez,, PT, PhD
Centro Universitario San Isidoro, affiliated with Pablo de Olavide University (Spain)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- CARE PROVIDER, OUTCOMES ASSESSOR
- Masking Details
- Participants will receive ET instructions from a clinician different from the one conducting the evaluations. None of the participants will be aware of their group assignment, as all will receive the same exercise dosage, but with differing decision-making approaches regarding the training. The physiotherapists delivering the ET sessions will not be involved in participant allocation. Due to the behavioural nature of ET, neither physiotherapists nor participants can be blinded, as they are required to deliver and perform the intervention protocols. To mitigate this bias, analyses will be performed by a statistician from the research team who will not participate in allocation, evaluation, or intervention. Additionally, participant data will be provided anonymously. In the event of any adverse effect or circumstance that may compromise participant health, records will be maintained in both paper and electronic formats and will remain accessible to all authorized researchers.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MSc.
Study Record Dates
First Submitted
July 29, 2026
First Posted
August 4, 2026
Study Start (Estimated)
September 1, 2026
Primary Completion (Estimated)
March 1, 2027
Study Completion (Estimated)
December 1, 2027
Last Updated
August 4, 2026
Record last verified: 2026-05
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, ICF
- Time Frame
- 01-09-2026 // 01-09-2027
To ensure the privacy and confidentiality of participants, all clinical data collected in the study will be anonymized prior to analysis. Names, identification numbers, and specific dates will be removed, and any indirect identifiers that could allow subject identification will be grouped and coded. The anonymization process will be conducted in accordance with current ethical and regulatory standards, ensuring that the data remain valid for statistical analysis without compromising individual privacy. All physical documents will be stored in locked filing cabinets within a secure area with restricted access. Electronic data will be entered into a secure, password-protected database specifically designed for the study. Access to the data will be limited to research team members listed in the study protocol. Data supporting the findings of this study will not be publicly available due to sensitivity but may be obtained from the corresponding author upon justified request. All data will